PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30066906-4 2018 We established two docetaxel-resistant prostate cancer cell lines, PC3/DR and DU145/DR, by culturing PC3 and DU145 cells in docetaxel in a dose-escalating manner. Docetaxel 19-28 proprotein convertase subtilisin/kexin type 1 Homo sapiens 101-104 30066906-4 2018 We established two docetaxel-resistant prostate cancer cell lines, PC3/DR and DU145/DR, by culturing PC3 and DU145 cells in docetaxel in a dose-escalating manner. Docetaxel 19-28 proprotein convertase subtilisin/kexin type 1 Homo sapiens 67-70 28928839-4 2017 In the present study, the differential gene expression between docetaxel-sensitive (PC3) and docetaxel-resistant (PC3DR2) prostate cancer cells was identified using DNA microarrays, western blot analysis and reverse transcription-quantitative polymerase chain reaction. Docetaxel 63-72 proprotein convertase subtilisin/kexin type 1 Homo sapiens 84-87 28872603-5 2017 Further, the antiproliferation activity of these compounds was examined in docetaxel-resistant (PC3R) and sensitive (PC3) human prostate cancer cell lines. Docetaxel 75-84 proprotein convertase subtilisin/kexin type 1 Homo sapiens 96-99 23788635-2 2013 In this study, tumorigenic potential was increased in the docetaxel-resistant residual prostate cancer cell lines (DRD, 1G7 and PC3DR) compared with parental cells (DU145 or PC3). Docetaxel 58-67 proprotein convertase subtilisin/kexin type 1 Homo sapiens 128-131 28133913-5 2017 siRNA manipulation of ZEB1 and ZEB2 in PC-3 and DU145 docetaxel-resistant sublines identified ZEB1, through its transcriptional repression of E-cadherin, to be a driver of both EMT and docetaxel resistance. Docetaxel 185-194 proprotein convertase subtilisin/kexin type 1 Homo sapiens 39-43 28109113-0 2017 [Effect of sodium phenylbutyrate on the sensitivity of PC3/DTX-resistant prostate cancer cells to docetaxel]. Docetaxel 98-107 proprotein convertase subtilisin/kexin type 1 Homo sapiens 55-58 28109113-2 2017 METHODS: A PC3/docetaxel-resistant human prostate cancer cell line PC3/DTX was induced and examined for proliferation, viability, and cell inhibition rate in the presence of SPB. Docetaxel 15-24 proprotein convertase subtilisin/kexin type 1 Homo sapiens 67-70 28109113-3 2017 The concentration of concentration of docetaxel required to kill 50% of PC3/DTX cells incubated with 0, 1, 2, and 4 mmol/L SPB was determined using MTT assay. Docetaxel 38-47 proprotein convertase subtilisin/kexin type 1 Homo sapiens 72-75 27318090-3 2016 In the present study, the docetaxel-resistant human PCa cell lines PC3-DR and DU-145-DR were established from the parental cell lines PC3 and DU-145, and the expression and role of INPP4B in docetaxel-resistant PCa cells were investigated. Docetaxel 26-35 proprotein convertase subtilisin/kexin type 1 Homo sapiens 67-70 27318090-3 2016 In the present study, the docetaxel-resistant human PCa cell lines PC3-DR and DU-145-DR were established from the parental cell lines PC3 and DU-145, and the expression and role of INPP4B in docetaxel-resistant PCa cells were investigated. Docetaxel 26-35 proprotein convertase subtilisin/kexin type 1 Homo sapiens 134-137 24888374-6 2015 The docetaxel IC50s of PC3 and PC/DX25 cells were 0.01 and 1.33 muM, respectively. Docetaxel 4-13 proprotein convertase subtilisin/kexin type 1 Homo sapiens 23-26 24888374-12 2015 Contrarily, overexpression of EGFR or recombinant EGF protein treatment could rescue PC3 cells from docetaxel-mediated cytotoxicity. Docetaxel 100-109 proprotein convertase subtilisin/kexin type 1 Homo sapiens 85-88 26182875-10 2015 RESULTS: The combination of desmopressin and docetaxel resulted in a significant inhibition of PC3 and LNCaP cell proliferation (p < 0.01). Docetaxel 45-54 proprotein convertase subtilisin/kexin type 1 Homo sapiens 95-98 19773444-4 2009 We used iTRAQ-mass spectrometry analysis to identify proteins associated with the development of Docetaxel resistance using Docetaxel-sensitive PC3 cells and Docetaxel-resistant PC3-Rx cells developed by Docetaxel dose escalation. Docetaxel 97-106 proprotein convertase subtilisin/kexin type 1 Homo sapiens 144-147 23192379-7 2013 Similar increases in cell survival were observed for LNCaP or PC3 cells treated with NE-derived medium in the presence of docetaxel. Docetaxel 122-131 proprotein convertase subtilisin/kexin type 1 Homo sapiens 62-65 22990129-0 2013 Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells. Docetaxel 36-45 proprotein convertase subtilisin/kexin type 1 Homo sapiens 124-127 22990129-0 2013 Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells. Docetaxel 93-102 proprotein convertase subtilisin/kexin type 1 Homo sapiens 124-127 22990129-4 2013 We observed an enhanced effect of docetaxel and octreotide given in combination or in sequence compared with either agent alone; this result was particularly evident when docetaxel was given before octreotide in PC3wt and when the two drugs were given together in PC3R cells. Docetaxel 34-43 proprotein convertase subtilisin/kexin type 1 Homo sapiens 212-215 20568904-6 2010 sCLU expression was studied using Western blotting on cultured prostate cells, PWR-1E, PC3 and PC3 Docetaxel resistant cells in the cytosol and culture medium. Docetaxel 99-108 proprotein convertase subtilisin/kexin type 1 Homo sapiens 95-98 19521959-3 2009 We have previously reported that sphingosine kinase 1 (SphK1) inhibition is a key step in docetaxel-induced apoptosis in the PC-3 PCa cell line and that pharmacologicalSphK1 inhibition is chemosensitizing in the docetaxel-resistant PCa LNCaP cell line. Docetaxel 90-99 proprotein convertase subtilisin/kexin type 1 Homo sapiens 125-129 19521959-4 2009 In this study we have addressed the mechanism of docetaxel-induced apoptosis of PC-3 cells and identified SphK1-dependent and -independent components. Docetaxel 49-58 proprotein convertase subtilisin/kexin type 1 Homo sapiens 80-84 19773444-4 2009 We used iTRAQ-mass spectrometry analysis to identify proteins associated with the development of Docetaxel resistance using Docetaxel-sensitive PC3 cells and Docetaxel-resistant PC3-Rx cells developed by Docetaxel dose escalation. Docetaxel 124-133 proprotein convertase subtilisin/kexin type 1 Homo sapiens 144-147 19773444-4 2009 We used iTRAQ-mass spectrometry analysis to identify proteins associated with the development of Docetaxel resistance using Docetaxel-sensitive PC3 cells and Docetaxel-resistant PC3-Rx cells developed by Docetaxel dose escalation. Docetaxel 124-133 proprotein convertase subtilisin/kexin type 1 Homo sapiens 144-147 19773444-4 2009 We used iTRAQ-mass spectrometry analysis to identify proteins associated with the development of Docetaxel resistance using Docetaxel-sensitive PC3 cells and Docetaxel-resistant PC3-Rx cells developed by Docetaxel dose escalation. Docetaxel 124-133 proprotein convertase subtilisin/kexin type 1 Homo sapiens 144-147 19773444-7 2009 The IC(50) for Docetaxel in the PC3-Rx cells was 13-fold greater than the parent PC-3 cell line (P = 0.004). Docetaxel 15-24 proprotein convertase subtilisin/kexin type 1 Homo sapiens 32-35 19773444-10 2009 Conversely, treating PC3-Rx cells with MIC-1 siRNA restored sensitivity to Docetaxel (P = 0.02). Docetaxel 75-84 proprotein convertase subtilisin/kexin type 1 Homo sapiens 21-24 19773444-11 2009 Knockdown of AGR2 expression in PC3 cells resulted in Docetaxel resistance (P = 0.007). Docetaxel 54-63 proprotein convertase subtilisin/kexin type 1 Homo sapiens 32-35 34281834-3 2021 MATERIALS AND METHODS: Parental human CRPC cell line PC3 (PC3/P) was continuously exposed to increasing doses of docetaxel, and a cell line resistant to docetaxel, PC3/R, was developed. Docetaxel 113-122 proprotein convertase subtilisin/kexin type 1 Homo sapiens 53-56 19153211-10 2009 Azacitidine sensitized PC3 and 22rv1 xenografts to DTX and cisplatin treatments. Docetaxel 51-54 proprotein convertase subtilisin/kexin type 1 Homo sapiens 23-26 18025278-3 2007 Based on initial findings that docetaxel-resistant PC3-DR and DU145-DR prostate tumor cell lines express tumor necrosis factor-related apoptosis inducing ligand (TRAIL) receptors, we examined whether TRAIL could be used as an alternative method to kill PC3-DR and DU145-DR cells. Docetaxel 31-40 proprotein convertase subtilisin/kexin type 1 Homo sapiens 51-54 16357178-2 2005 We took advantage of the known differential effect of camptothecin and docetaxel on human PC-3 and LNCaP prostate cancer cells to determine their effect on sphingosine kinase-1 (SphK1) activity and subsequent ceramide/sphingosine 1-phosphate (S1P) balance in relation with cell survival. Docetaxel 71-80 proprotein convertase subtilisin/kexin type 1 Homo sapiens 90-94 11156248-11 2000 Although the taxanes, paclitaxel or docetaxel, as single agents markedly inhibited the growth of A431, LX-1, SK-LC-16, TSU-PR1, and PC-3, when combined with ZD1839, partial or complete regression was usually seen. Docetaxel 36-45 proprotein convertase subtilisin/kexin type 1 Homo sapiens 132-136 34281834-3 2021 MATERIALS AND METHODS: Parental human CRPC cell line PC3 (PC3/P) was continuously exposed to increasing doses of docetaxel, and a cell line resistant to docetaxel, PC3/R, was developed. Docetaxel 113-122 proprotein convertase subtilisin/kexin type 1 Homo sapiens 58-63 34281834-3 2021 MATERIALS AND METHODS: Parental human CRPC cell line PC3 (PC3/P) was continuously exposed to increasing doses of docetaxel, and a cell line resistant to docetaxel, PC3/R, was developed. Docetaxel 153-162 proprotein convertase subtilisin/kexin type 1 Homo sapiens 164-167 34281834-8 2021 Furthermore, additional treatment of PC3/R with a specific inhibitor of AKT significantly enhanced the cytotoxic activity of docetaxel but not that of cabazitaxel. Docetaxel 125-134 proprotein convertase subtilisin/kexin type 1 Homo sapiens 37-40